<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274778</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-IOR-001</org_study_id>
    <nct_id>NCT03274778</nct_id>
  </id_info>
  <brief_title>Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells</brief_title>
  <official_title>An Exploratory proof-of Mechanism Study to Assess the Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells and Additional Immune Subsets in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Institute of Southern Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after&#xD;
      histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days&#xD;
      followed by a prostatectomy thereafter.&#xD;
&#xD;
      Tumor material and blood samples will be analysed before, during and after the treatment with&#xD;
      Ruxolitinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with suspected localized prostate cancer will undergo biopsies spotting different&#xD;
      prostate sites, as per standard clinical practice. Patients with histologically confirmed&#xD;
      prostate adenocarcinoma and candidate for prostatectomy, after signing the Informed Consent&#xD;
      Form, will receive Ruxolitinib for 4 weeks (the time normally elapsing between histological&#xD;
      diagnosis and surgery) and will thereafter undergo prostatectomy.&#xD;
&#xD;
      Remaining biological material from the diagnosis and the prostatectomy will be sent to the&#xD;
      Molecular Oncology Laboratory for molecular analysis.&#xD;
&#xD;
      In addition, blood samples will be drawn before, during Ruxolitinib treatment (Week 2), at&#xD;
      the end of treatment (Week 4), and after prostatectomy (Week 5), to assess the frequency and&#xD;
      subtype of immune subsets and the circulating levels of cytokines and secreted.&#xD;
&#xD;
      Patients will be monitored for occurrence of adverse events/surgical complications during&#xD;
      treatment and up to 4 weeks after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Recruitment difficulty due to eligibility criteria.&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor immune response</measure>
    <time_frame>9 wks</time_frame>
    <description>Tumor immune response modification induced by Ruxolitinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pSTAT3</measure>
    <time_frame>5 wks</time_frame>
    <description>Decrease of pSTAT3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>6 wks</time_frame>
    <description>Reduction of cytokines associated to myeloid cells recruitment and tumor-promoting factors (e.g. IL8, IL6, TGF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KI-67</measure>
    <time_frame>9 wks</time_frame>
    <description>Reduction by 50% of KI-67</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers</measure>
    <time_frame>5 wks</time_frame>
    <description>Increase of senescence and apoptosis markers (p16, p21, Beta-galactosidase, Caspase-3, Caspase-8)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Ruxolitinib 20mg BID for 28 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib 20 MG</intervention_name>
    <description>tablets</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Jakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  Histological diagnosis of prostate adenocarcinoma&#xD;
&#xD;
          -  Stage ≥T2b for which surgery is indicated&#xD;
&#xD;
          -  No distant metastasis (M0)&#xD;
&#xD;
          -  NLR ≥3 in the blood or NLR ≥3 in the tumor biopsies or a percentage of MDSCs ≥ 30% in&#xD;
             the tumour biopsies&#xD;
&#xD;
          -  PS (ECOG scale) 0-1&#xD;
&#xD;
          -  Adequate hepatic function: ALT and ASAT ≤ 2.5 x ULN, Bilirubin ≤ 1.5 ULN (exception if&#xD;
             Gilbert's syndrome ≤ 2.5 x ULN)&#xD;
&#xD;
          -  Adequate renal function: calculated creatinine clearance ≥ 50 ml/min according to the&#xD;
             formula of Cockcroft-Gault&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dl, leukocyte count ≥ 4.0 x 103/µl, platelet count ≥ 200 x 103/µl&#xD;
&#xD;
          -  Informed Consent as documented by the patient's signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of coagulation disorders and normal INR&#xD;
&#xD;
          -  Significant cardiovascular disorders in the last 12 months&#xD;
&#xD;
          -  Other clinically significant concomitant disease states which in the opinion of the&#xD;
             Investigator may represent contraindications to study participation&#xD;
&#xD;
          -  Known or suspected non-compliance&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study&#xD;
&#xD;
          -  Ongoing treatment with strong CYP3A4 inhibitors or dual CYP2C9 and CYP3A4 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Alimonti, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Oncology Research (IOR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Andrea Alimonti</investigator_full_name>
    <investigator_title>Prof. dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

